Costs associated with febrile neutropenia in the US

PharmacoEconomics

Volumn 30, Issue 9, 2012, Pages 809-823

  Michels, Shannon L ^a   Barron, Rich L ^b   Reynolds, Matthew W ^a   Smoyer Tomic, Karen ^c   Yu, Jingbo ^c   Lyman, Gary H ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b AMGEN INC   (United States)

^c HEALTHCORE INC   (United States)

^d DUKE CANCER INSTITUTE   (United States)

Author keywords

antineoplastics; cost analysis; febrile neutropenia; resource use

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHODGKIN LYMPHOMA; OUTPATIENT; OUTPATIENT CARE; OVARY CANCER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL; UNITED STATES;

ANTINEOPLASTIC AGENTS; BONE MARROW; COHORT STUDIES; DELIVERY OF HEALTH CARE; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; FEVER; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84864988099     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11592980-000000000-00000     Document Type: Article

References (35)

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 2004 Jan 15; 100 (2): 228-237 (Pubitemid 38063629)
2. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 May 15; 106 (10): 2258-2266 (Pubitemid 43673249)
3. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003 Oct 1; 1 (1): 23-35
4. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. NEngl J Med 1993 May 6, 1993; 328 (18): 1323-1332
5. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwiDe study of oncology practice. J Natl Compr Canc Netw 2008 Feb; 6 (2): 109-118 (Pubitemid 351340522)
6. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-graDe non-Hodgkin lymphoma. Cancer 2003 Dec 1; 98 (11): 2402-2409 (Pubitemid 37466655)
7. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-graDe non- Hodgkins lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003 Dec; 44 (12): 2069-2076
8. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005 Jun-Jul; 10 (6): 427-437
9. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005 May 1; 103 (9): 1916-1924 (Pubitemid 40563265)
10. Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy.AnnOncol 2008Mar; 19 (3): 454-460 (Pubitemid 351325664)
11. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008 Feb 1; 26 (4): 606-611 (Pubitemid 351264355)
12. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005 Feb 20; 23 (6): 1178-1184 (Pubitemid 46202274)
13. Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010 Feb 1; 116 (3): 742-748
14. Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005 Jan-Feb; 8 (1): 47-52 (Pubitemid 40293640)
15. Trueman P. Prophylactic G-CSF in patients with early-stage breast cancer: A health economic review. Br J Cancer 2009 Sep; 101 Suppl. 1: S15-7
16. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist 2007 Apr; 12 (4): 478-483 (Pubitemid 46698725)
17. Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia- related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009 Oct; 15 (8): 669-682
18. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006 Sep; 14 (9): 901-909
19. Chang J. Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000 Apr; 36 Suppl. 1: S11-4
20. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 Mar 15; 34 (6): 730-751 (Pubitemid 34194843)
21. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007 Jul 20; 25 (21): 3158-3167 (Pubitemid 47218066)
22. Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003; (3): CD003039
23. Cosler LE, Eldar-Lissai A, Culakova E, et al. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: Effect on costs from a hospital perspective. Pharmacoeconomics 2007; 25 (4): 343-351 (Pubitemid 46607384)
24. Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007 Apr; 12 (4): 484-494 (Pubitemid 46698726)
25. von Minckwitz G, SchwenkglenksM, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis. Eur J Cancer 2009 Mar; 45 (4): 608-617
26. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997 Aug; 25 (2): 247-259 (Pubitemid 27364722)
27. Heckman J, Ichimura H, Todd P. Matching as an econometric evaluation estimator: Evidence from evaluating a job training programme. Rev Econ Stud 1997; 64: 605-654 (Pubitemid 127466391)
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 Apr 1; 70 (1): 41-55
29. Rosenbaum P, RubinD. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985 Feb; 39 (1): 33-38
30. Gold MR. Cost-effectiveness in health andmedicine.New York: Oxford University Press, 1996
31. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993
32. Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010 Dec 1; 116 (23): 5555-5563
33. Mayordomo JI, Lopez A, Vinolas N, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009 Oct; 25 (10): 2533-2542
34. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008 Feb; 6 (2): 122-174 (Pubitemid 351340523)
35. Chen-Hardee S, Chrischilles EA, VoelkerMD, et al. Populationbased assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkins lymphoma (United States). Cancer Causes Control 2006 Jun; 17 (5): 647-654(Pubitemid 43668322)